CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (V):



Formula (V);

wherein:

R^1 and R^2 are each independently H, -(C_1-C_6)alkyl, -(C_1-C_6)alkyl-OR^{23}, -$CH_2CH(OH)CH_2NH_2$, -CH_2CH(heterocycloalkyl)CH_2NH_2, -$CH_2C(O)NH_2$, -$CH_2C(O)N(H)CH_2CN$, -(C_1-C_6)alkyl-$C(O)OR^{23}$, -(C_1-C_6)alkyl-$NR^{21}R^{22}$, -(C_1-C_6)alkyl-$C(O)NR^{25}R^{26}$, -(C_1-C_6)alkyl-$N(R^{23})C(O)(C_1$-C_6)alkyl$NR^{21}R^{22}$, -(C_1-C_6)alkyl-$N(R^{23})C(O)(C_1$-C_6)alkyl, -(C_1-C_6)alkyl-$C(O)N(R^{23})(C_1$-C_6)alkyl, -(C_1-C_6)alkyl-$C(O)N(R^{23})(C_1$-C_6)alkyl-heterocycloalkyl, -(C_1-C_6)alkyl-$NR^{23}C(=NH)NR^{21}R^{22}$, -($C_1$-$C_6$)alkyl-$NR^{23}C(=NH)R^{23}$, -($C_1$-$C_6$)alkyl-[($C_1$-$C_6$)alkyl-$NR^{21}R^{22}]_2$, -($C_1$-$C_6$)heteroalkyl, or optionally substituted heterocycloalkyl;

or R^1 and R^2 and the atoms to which they are attached form an optionally substituted heterocycloalkyl ring;

R^6, R^7, and R^8 are each independently H, fluoro, hydroxyl, amino, optionally substituted alkyl, heteroalkyl, or -(C_1-C_6)alkyl;

R^9 is H, -(C_1-C_6)alkyl, -(C_1-C_6)haloalkyl, or -(C_3-C_6)cycloalkyl;

R^{10} is H, -(C_1-C_6)alkyl, -(C_1-C_6)haloalkyl, or -(C_3-C_6)cycloalkyl;

or R^9 and R^{10} are combined to form a heterocycloalkyl or cycloalkyl ring

R^{11} and R^{12} are each independently H, -NH_2, -(C_1-C_6)alkyl, -(C_1-C_6)alkyl-OR^{23}, -(C_1-C_6)alkyl-SR^{23}, -(C_1-C_6)alkyl-$C(O)OR^{23}$, -(C_1-C_6)alkyl-$NR^{21}R^{22}$, -(C_1-C_6)alkyl-$NR^{23}OR^{23}$, -(C_1-C_6)alkyl-$NHC(O)NR^{23}OR^{23}$, -(C_1-C_6)alkyl-O-(C_1-C_6)alkyl-$NR^{25}R^{26}$, -(C_1-C_6)alkyl-CN, -(C_1-C_6)alkyl-$NR^{23}C(O)R^{23}$, -(C_1-C_6)alkyl-$C(O)NR^{25}R^{26}$, -(C_1-C_6)heteroalkyl-CO_2H, -(C_1-C_6)alkyl-S(O)(C_1-C_6)alkyl, -(C_1-C_6)alkyl-N(H)CH=NH, -(C_1-C_6)alkyl-$C(NH_2)$=NH, -(C_1-C_6)alkyl-N(H)C(=NH)NH_2, -(C_1-C_6)alkyl-N(H)$S(O)_2NR^{25}R^{26}$, -(C_1-C_6)alkyl-N(H)$S(O)_2(C_1$-C_6)alkyl, -(C_1-C_6)alkyl-N(H)-$C(O)NR^{25}R^{26}$, -(C_1-C_6)alkylC(O)N(H)[optionally substituted(C_2-C_6)alkyl]-OR^{23}, -(C_1-C_6)alkylN(H)C(O)(C_1-C_6)alkyl-OR^{23}, -(C_1-C_6)alkylC(O)N(H)heterocycloalkyl, -(C_1-C_6)alkylC(O)$NR^{25}R^{26}$, -(C_1-C_6)alkyl-N(H)-C(O)-(C_1-C_6)alkyl-$NR^{25}R^{26}$, -(C_1-C_6)alkyl-N(H)-(C_1-C_6)alkylC(O)$NR^{25}R^{26}$, -(C_1-C_6)alkyl-

heterocycloalkyl, optionally substituted -(C_1-C_6)alkyl-N(H)heterocycloalkyl, or -(C_1-C_6)alkyl-heteroaryl;

or R^{11} and R^{18} are combined to form an optionally substituted heterocycloalkyl ring; and R^{12} is H;

R^{15}, R^{16}, R^{17}, and R^{18} are each independently H, -(C_1-C_6)alkyl, -(C_3-C_6)cycloalkyl, -(C_1-C_6)alkyl-OR^{23}, -(C_1-C_6)alkyl-C(O)OR^{23}, or -(C_1-C_6)alkyl-$NR^{21}R^{22}$;

X is optionally substituted heteroaryl;

Y is a bond, -O-, -S-, optionally substituted -(C_1-C_6)alkyl-, -(C_2-C_6)alkenyl-, -(C_2-C_6)alkynyl, -(C_1-C_6)alkyl-N(R^{24})(C_1-C_6)alkyl-, -O-(C_1-C_6)alkyl-, -O(C_6-C_{10})aryl-, -N(R^{24})(C_1-C_6)alkyl-, -N(R^{24})SO_2(C_1-C_6)alkyl-, -N(R^{24})C(O)(C_1-C_6)alkyl-, -C(O)(C_1-C_6)alkyl-, -S(C_1-C_6)alkyl-, -SO_2(C_1-C_6)alkyl-, -C(O)NH(C_1-C_6)alkyl-, optionally substituted -(C_3-C_7)cycloalkyl-, optionally substituted -C(O)N(R^{24})aryl-, optionally substituted -N(R^{24})C(O)aryl-, optionally substituted -N(R^{24})SO_2aryl-, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;

Z is H, halogen, -NH_2, -CN, -CF_3, -CO_2H, -(C_1-C_{12})alkyl, -(C_2-C_{12})alkenyl, -CH=((C_3-C_7)cycloalkyl), -(C_2-C_{12})alkynyl, -C(O)$NR^{25}R^{26}$, -O-(C_1-C_{12})alkyl, -S-(C_1-C_{12})alkyl, -O-[optionally substituted (C_3-C_7)cycloalkyl], -O-(C_1-C_6)alkyl-OR^{23}, -(C_1-C_{12})alkyl-OR^{23}, -(C_1-C_{12})alkyl-CN, -S-(C_1-C_{12})alkyl, -N(R^{24})(C_1-C_{12})alkyl, -N(R^{24})C(O)(C_1-C_{12})alkyl, optionally substituted -(C_3-C_7)cycloalkyl, -(C_1-C_6)alkyl-(C_3-C_7)cycloalkyl, -(C_1-C_6)alkyl-heterocycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;

each R^{21} and R^{22} is independently H, -(C_1-C_6)alkyl, -(C_1-C_6)heteroalkyl, -(C_1-C_6)alkyl-CO_2H, -C(O)(C_1-C_6)alkyl, -C(O)O(C_1-C_6)alkyl, -C(O)O(C_1-C_6)haloalkyl, -C(=NH)(C_1-C_6)alkyl, -C(=NH)N(R^{31})$_2$, -C(O)N(R^{31})$_2$, or -SO_2N(R^{31})$_2$; or R^{21} and R^{22} and the nitrogen atom to which they are attached form a heterocycloalkyl ring;

each R^{31} is independently H or -(C_1-C_6)alkyl; or two R^{31} and the nitrogen atom to which they are attached form a heterocycloalkyl ring;

each R^{23} is independently H or -(C_1-C_6)alkyl;

each R^{24} is independently H or -(C_1-C_6)alkyl;

each R^{25} and R^{26} is independently H or optionally substituted -(C_1-C_6)alkyl;

or R^{25} and R^{26} and the nitrogen atom to which they are attached form a heterocycloalkyl ring;

each R^{27} is independently halogen, -$NR^{23}R^{24}$, -NHC(O)R^{23}, -NHC(O)$NR^{23}R^{24}$, nitro, hydroxyl, optionally substituted -(C_1-C_6)alkyl, optionally substituted -(C_1-C_6)heteroalkyl, optionally substituted -(C_1-C_6)heteroalkyloxy, optionally substituted -(C_1-C_6)heteroalkylamino, -(C_1-C_6)alkoxy, -C(O)(C_1-C_6)alkyl, or -S(O)$_2$(C_1-C_6)alkyl;

or R^1 and R^{27} and the atoms to which they are attached form an optionally substituted 5- or 6-membered heterocycloalkyl ring;

each R^{28} is independently halogen, -$NR^{23}R^{24}$, -NHC(O)R^{23}, -NHC(O)$NR^{23}R^{24}$, nitro, hydroxyl, optionally substituted -(C_1-C_6)alkyl, optionally substituted -(C_1-C_6)heteroalkyl, optionally substituted -

(C_1-C_6)heteroalkyloxy, optionally substituted -(C_1-C_6)heteroalkylamino, -(C_1-C_6)alkoxy, -C(O)(C_1-C_6)alkyl, or -$S(O)_2$(C_1-C_6)alkyl;

or R^2 and R^{28} and the atoms to which they are attached form an optionally substituted 5- or 6-membered heterocycloalkyl ring;

p is 0, 1, or 2; and

q is 0, 1, or 2;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^6, R^7, and R^8 are H.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{15} and R^{16} are H.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{17} is -CH_3.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{18} is H.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{10} is H and R^9 is -(C_1-C_6)alkyl.

7. The compound of claim 6, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{10} is H and R^9 is -CH_3.

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{12} is H and R^{11} is -(C_1-C_6)alkyl-OR^{23}.

9. The compound of claim 8, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{12} is H and R^{11} is -CH_2CH_2OH.

10. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{12} is H and R^{11} is -(C_1-C_6)alkyl.

11. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{12} is H and R^{11} is -(C_1-C_6)alkyl-$NR^{21}R^{22}$.

12. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{12} is H and R^{11} is -(C_1-C_6)alkyl-NH_2.

13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt or solvate thereof, wherein X is heteroaryl monosubstituted or disubstituted with a substituent independently selected from halogen, -CN, optionally substituted -(C_1-C_6)alkyl, optionally substituted -O-(C_1-C_6)alkyl, OR^{23}, -$NR^{25}R^{26}$, and -NO_2.

14. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt or solvate thereof, wherein X is pyridinyl or pyrimidinyl monosubstituted or disubstituted with a substituent independently selected from halogen, -CN, optionally substituted -(C_1-C_6)alkyl, optionally substituted -O-(C_1-C_6)alkyl, OR^{23}, -$NR^{25}R^{26}$, or -NO_2.

15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is optionally substituted aryl.
16. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is optionally substituted heteroaryl.
17. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is optionally substituted (C_3-C_7)cycloalkyl.
18. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is optionally substituted heterocycloalkyl.
19. A pharmaceutical composition comprising the compound of any one of claims 1-18, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
20. Use of a compound of any one of claims 1-18, or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for treatment of a bacterial infection in a patient.
21. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.